AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20845219 — intervention group
Group type: COMPARATOR
Intervention: Blocked scheduling (control group for basketball passes)
Number of subjects: 0
Study 20845219 — intervention group
Group type: COMPARATOR
Intervention: Random scheduling (control group for basketball passes)
Number of subjects: 0
Study 15735057 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragms of patients with severe COPD
Number of subjects: 19
Study 15735057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe COPD
Number of subjects: 19
Study 15735057 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle endothelial nitric oxide synthase in patients with severe COPD
Number of subjects: 19
Study 15735057 — intervention group
Group type: COMPARATOR
Intervention: Muscle nitrotyrosine levels in patients with severe COPD
Number of subjects: 19
Study 11219761 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum effort exerted by operators
Number of subjects: 25
Study 11219761 — intervention group
Group type: EXPERIMENTAL
Intervention: Power handtool operation
Number of subjects: 25
Study 9778066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg)
Number of subjects: 262
Study 9778066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 7888418 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD-seasonal patients
Number of subjects: 42
Study 3150319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal buserelin 400 micrograms three times daily for 6 months
Number of subjects: 13
Study 3150319 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (6 months after stopping buserelin)
Number of subjects: 13
Study 3150319 — intervention group
Group type: EXPERIMENTAL
Intervention: During treatment with buserelin
Number of subjects: 13
Study 30668196 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anti-Müllerian hormone (AMH) levels measured using VIDAS®
Number of subjects: 428
Study 30668196 — intervention group
Group type: COMPARATOR
Intervention: AMH cutoff value of 42.1 pmol/L
Number of subjects: 428
Study 30668196 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH levels in PCOS women with three Rotterdam criteria or hyperandrogenism
Number of subjects: 428
Study 30668196 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH levels in PCOS
Number of subjects: 428
Study 29936571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 28
Study 29936571 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 28
Study 29936571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29936571 — intervention group
Group type: COMPARATOR
Intervention: Non-OA controls
Number of subjects: 28
Study 27357222 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented monoblock cruciate‐retaining (CR) tibial component (TM)
Number of subjects: 41
Study 27357222 — intervention group
Group type: COMPARATOR
Intervention: Cemented NexGen Option CR tibial component
Number of subjects: 41
Study 23962173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment
Number of subjects: 60
Study 23962173 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study 22241819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 212
Study 22241819 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 212
Study 19103558 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin, 2 x 166 mg/day for 3 months
Number of subjects: 32
Study 19103558 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the first 3 months
Number of subjects: 32
Study 17928596 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization with S. pneumoniae, M. catarrhalis, H. influenzae, or a combination of these organisms
Number of subjects: 321
Study 15385732 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 at 5 microg/kg/h
Number of subjects: 40
Study 15385732 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 at 40 microg/kg/h
Number of subjects: 40
Study 15385732 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 at 80 microg/kg/h
Number of subjects: 40
Study 15385732 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 at 160 microg/kg/h
Number of subjects: 40
Study 15385732 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 (all doses)
Number of subjects: 40
Study 11519973 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified cow's milk (7.0 or 14.9 mg Fe l(‐1))
Number of subjects: 36
Study 11519973 — intervention group
Group type: COMPARATOR
Intervention: Unfortified cow's milk
Number of subjects: 36
Study 9683847 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and adriamycin
Number of subjects: 29
Study 9683847 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with ifosfamide and etoposide added to cisplatin and adriamycin for poor histologic response
Number of subjects: 29
Study 9683847 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 29
Study 8150787 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid function indices (TSH, T3, T4) in ADHD subjects
Number of subjects: 53
Study 8150787 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (age and gender-matched), N=41
Number of subjects: 53
Study 3207530 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 12
Study 3207530 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 12
Study 31990490 — intervention group
Group type: EXPERIMENTAL
Intervention: accelerated intermittent theta burst stimulation (aiTBS) applied to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 40
Study 29352071 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive diuresis with high-dose loop diuretics (median 560 mg IV furosemide equivalents)
Number of subjects: 283
Study 29352071 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive diuresis with high-dose loop diuretics
Number of subjects: 283
Study 27510532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation (ONS) during HD sessions for 12 weeks
Number of subjects: 36
Study 27510532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation (ONS) + Resistance Exercise (RE) during HD sessions for 12 weeks
Number of subjects: 36
Study 27510532 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving ONS
Number of subjects: 36
Study 27510532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving ONS + RE
Number of subjects: 36
Study 24992949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone for 8 days in tapering doses
Number of subjects: 265
Study 24992949 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic prednisolone at a dose of 62.5 mg/ml once a day for 3 consecutive days
Number of subjects: 265
Study 22995032 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil applied twice daily for 5 weeks
Number of subjects: 19
Study 22995032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil applied twice daily for 4 weeks
Number of subjects: 19
Study 22995032 — intervention group
Group type: COMPARATOR
Intervention: Olive oil compared to sunflower seed oil
Number of subjects: 19
Study 20391510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg every other day)
Number of subjects: 39144
Study 20391510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39144
Study 18232726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose olanzapine (mean dose, 34 mg/day)
Number of subjects: 40
Study 18232726 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (mean dose, 564 mg/day)
Number of subjects: 40
Study 16763775 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps (EC) participants
Number of subjects: 113
Study 16763775 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps (EC) participants with low activity at baseline
Number of subjects: 113
Study 16763775 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group with low activity at baseline
Number of subjects: 113
Study 16763775 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously active EC participants
Number of subjects: 113
Study 11860612 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 micrograms in 0.1 ml saline)
Number of subjects: 20
Study 11860612 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 ml)
Number of subjects: 20
Study 11860612 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 20
Study 10353373 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple feature search
Number of subjects: 0
Study 10353373 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoined feature search
Number of subjects: 0
Study 10353373 — intervention group
Group type: COMPARATOR
Intervention: Experimental test session
Number of subjects: 0
Study 10353373 — intervention group
Group type: EXPERIMENTAL
Intervention: Target detection
Number of subjects: 0
Study 7866980 — intervention group
Group type: EXPERIMENTAL
Intervention: COACHING protocol
Number of subjects: 18
Study 7866980 — intervention group
Group type: COMPARATOR
Intervention: NOT‐COACHED (usual care)
Number of subjects: 18
Study 1772457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysate injection (10 ml, 400 mg)
Number of subjects: 12
Study 1772457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysate infusion (500 ml, 4 g)
Number of subjects: 12
Study 1772457 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (saline)
Number of subjects: 12
Study 7043868 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckling operation with drainage of subretinal fluid
Number of subjects: 120
Study 7043868 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling operation without drainage of subretinal fluid
Number of subjects: 120
Study 7043868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (drainage and nondrainage)
Number of subjects: 120
Study 31094772 — intervention group
Group type: EXPERIMENTAL
Intervention: High MAP (HMAP; 70-80 mm Hg)
Number of subjects: 176
Study 31094772 — intervention group
Group type: COMPARATOR
Intervention: Low MAP (LMAP; 40-50 mm Hg)
Number of subjects: 176
Study 28822007 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 3 dose-dense cycles of intensified epirubicin, paclitaxel, and cyclophosphamide (ETC)
Number of subjects: 163
Study 28822007 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles concurrent epirubicin and cyclophosphamide followed by 10 cycles of weekly paclitaxel combined with 4 cycles capecitabine (EC-TX)
Number of subjects: 163
Study 28822007 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC treatment
Number of subjects: 163
Study 24206399 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire FR embolectomy device
Number of subjects: 690
Study 24206399 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 690
Study 24206399 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 690
Study 24227635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50mg
Number of subjects: 39
Study 24227635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22558108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) - daily supplemental RUTF (high-protein peanut-based paste) for 14 days
Number of subjects: 180
Study 22558108 — intervention group
Group type: COMPARATOR
Intervention: Control group - no supplemental food
Number of subjects: 180
Study 22558108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF)
Number of subjects: 180
Study 19523596 — intervention group
Group type: COMPARATOR
Intervention: RCTs published in high-ranked journals
Number of subjects: 261
Study 19523596 — intervention group
Group type: COMPARATOR
Intervention: RCTs published in low-ranked journals
Number of subjects: 261
Study 19523596 — intervention group
Group type: COMPARATOR
Intervention: Pre-CONSORT period (1988-1995)
Number of subjects: 261
Study 19523596 — intervention group
Group type: COMPARATOR
Intervention: Post-CONSORT period (1996-2008)
Number of subjects: 261
Study 17544888 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO(2) increased from 30 to 40 mmHg
Number of subjects: 17
Study 17544888 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO(2) increased to 50 mmHg
Number of subjects: 17
Study 17544888 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO(2) returned to 30 mmHg
Number of subjects: 17
Study 17544888 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO(2) increased
Number of subjects: 17
Study 15385367 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Number of subjects: 10
Study 15385367 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal position
Number of subjects: 10
Study 15385367 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Number of subjects: 10
Study 15385367 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 10
Study 15385367 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 10
Study 11442499 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (1600 mg/d)
Number of subjects: 535
Study 11442499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 10588606 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol
Number of subjects: 11
Study 8573450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 346
Study 8573450 — intervention group
Group type: COMPARATOR
Intervention: Non-oophorectomized women
Number of subjects: 346
Study 8573450 — intervention group
Group type: COMPARATOR
Intervention: Oophorectomized women
Number of subjects: 346
Study 2150785 — intervention group
Group type: EXPERIMENTAL
Intervention: Single administration of 250 mg of caffeine (a)
Number of subjects: 7
Study 2150785 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of 250 mg caffeine per day for 5 days (c)
Number of subjects: 7
Study 2150785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (p)
Number of subjects: 7
Study 91500 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different stimulation frequencies during the task
Number of subjects: 84
Study 91500 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different stimulation frequencies during rest
Number of subjects: 84
Study 91500 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 different stimulation frequencies during the final rest period
Number of subjects: 84
Study 91500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower stimulation frequencies
Number of subjects: 84
Study 30346186 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CBT (N = 52)
Number of subjects: 102
Study 30346186 — intervention group
Group type: COMPARATOR
Intervention: CBT (N = 50)
Number of subjects: 102
Study 27041269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu aScope 3 Slim
Number of subjects: 20
Study 27041269 — intervention group
Group type: COMPARATOR
Intervention: Olympus LF-GP
Number of subjects: 20
Study 25134312 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturising leave‐on lotion (LOL) containing 10% glycerol, applied 3 times per week for 8 weeks.
Number of subjects: 0
Study 23588449 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary vitamin K intake
Number of subjects: 132
Study 23588449 — intervention group
Group type: COMPARATOR
Intervention: Low dietary vitamin K intake
Number of subjects: 132
Study 20358470 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 servings/day of botanically defined fruits and vegetables for 2 weeks
Number of subjects: 28
Study 20358470 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT1A1*28 polymorphism
Number of subjects: 28
Study 18329881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic tumors
Number of subjects: 58
Study 18329881 — intervention group
Group type: COMPARATOR
Intervention: Solid tumors
Number of subjects: 58
Study 16372492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous irinotecan plus oral ciclosporin
Number of subjects: 34
Study 12730797 — intervention group
Group type: COMPARATOR
Intervention: SR 1 g/day
Number of subjects: 513
Study 12730797 — intervention group
Group type: COMPARATOR
Intervention: SR 2 g/day
Number of subjects: 513
Study 12730797 — intervention group
Group type: EXPERIMENTAL
Intervention: SR (higher-dose group)
Number of subjects: 513
Study 12730797 — intervention group
Group type: COMPARATOR
Intervention: SR
Number of subjects: 513
Study 10378604 — intervention group
Group type: EXPERIMENTAL
Intervention: Short chain fatty acid enemas
Number of subjects: 19
Study 10378604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8675080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg four times daily orally)
Number of subjects: 10
Study 8675080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1736933 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg/daily) with weight loss
Number of subjects: 878
Study 1736933 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/daily) with weight loss
Number of subjects: 878
Study 1736933 — intervention group
Group type: COMPARATOR
Intervention: Placebo with usual diet
Number of subjects: 878
Study 1736933 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone with sodium restriction
Number of subjects: 878
Study 1736933 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol with sodium restriction
Number of subjects: 878
Study 1736933 — intervention group
Group type: COMPARATOR
Intervention: Placebo with weight reduction (lost more than 4.5 kg)
Number of subjects: 878
Study 1736933 — intervention group
Group type: COMPARATOR
Intervention: Sodium restriction (reduced sodium to less than 70 mEq daily)
Number of subjects: 878
Study 1736933 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss/atenolol subgroup
Number of subjects: 878
Study 1736933 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual diet/chlorthalidone subgroup
Number of subjects: 878
Study 1736933 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 878
Study 1736933 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone and usual diet
Number of subjects: 878
Study 6228913 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1 g/day)
Number of subjects: 604
Study 6228913 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1 g) + Dipyridamole (225 mg)
Number of subjects: 604
Study 6228913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 604
Study 3894598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 0
Study 29969473 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma concentrations of IL‐6, IL‐8, and IL‐10 at wound closure and 24 hours after surgery
Number of subjects: 96
Study 29969473 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6 and IL‐8 levels above the 3rd quartile measured on the first postoperative day
Number of subjects: 96
Study 26407603 — intervention group
Group type: COMPARATOR
Intervention: ABT-436 100 mg
Number of subjects: 29
Study 26407603 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-436 500 mg
Number of subjects: 29
Study 26407603 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-436 800 mg
Number of subjects: 29
Study 26407603 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-436 200 mg (morning regimen)
Number of subjects: 29
Study 26407603 — intervention group
Group type: COMPARATOR
Intervention: ABT-436 200 mg (evening regimen)
Number of subjects: 29
Study 25503455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 114
Study 25503455 — intervention group
Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 114
Study 25503455 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 114
Study 22683955 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage
Number of subjects: 40
Study 22683955 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative regime (nothing by mouth)
Number of subjects: 40
Study 20152042 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (1500 mg per day for 6 weeks) followed by a 12-week progressive walking program (3000 to 6000 steps/day)
Number of subjects: 36
Study 18518726 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-slice computed tomography (CT) angiography
Number of subjects: 244
Study 18518726 — intervention group
Group type: COMPARATOR
Intervention: Conventional digital subtraction (DS) angiography
Number of subjects: 244
Study 15782751 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia guideline implementation
Number of subjects: 510
Study 14602757 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release glipizide
Number of subjects: 15
Study 14602757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide GITS
Number of subjects: 15
Study 14602757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 15
Study 14602757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 15
Study 11177189 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fat content breakfast (M)
Number of subjects: 24
Study 11177189 — intervention group
Group type: COMPARATOR
Intervention: Low fat content breakfast (L)
Number of subjects: 24
Study 8792788 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance interventions
Number of subjects: 16
Study 1614804 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa2 (reaferon) combined with antioxidants (tocopherol)
Number of subjects: 73
Study 1614804 — intervention group
Group type: COMPARATOR
Intervention: Tocopherol alone
Number of subjects: 73
Study 1614804 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 73
Study 6203288 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (opiate antagonist)
Number of subjects: 0
Study 30699314 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal-thoracic-artery grafting
Number of subjects: 3102